Arrhythmia Clinical Unit - Instituto do Coração - HCFMUSP
São Paulo, 05403010, Brazil
NCT Number: NCT04361006
A randomized pilot study to evaluate safety and efficacy endpoints for treatment of para-hisian accessory pathways according to two different strategies of lesion formation.
These patients will be divided into 2 groups with different strategies of treatment: group 1 treated with radiofrequency (RF) ablation, group 2 with cryotherapy (CRYO).
The primary outcome will be the recurrence rate of accessory pathway conduction after one year of follow-up. Secondary endpoints will be immediate success and rate of permanent atrioventricular (AV) block.
Looking for future studies?
Notify Me12 year and older
All sexes
Interventional
Not applicable
São Paulo, 05403010, Brazil
This is a randomized study on the safety and efficacy for percutaneous ablation of para-hisian accessory pathways according to two different modalities: radiofrequency (RF) or cryotherapy.
Thirty patients with symptomatic or high-risk para-hisian accessory pathways, documented by previous electrophysiological study (EPS), referred to percutaneous catheter ablation, will be enrolled in this trial.
After informed consent, these patients will be randomized in 2 groups with different current established strategies of invasive treatment. Group I: electrophysiological mapping and ablation with radiofrequency (RF) focal lesion formation.
Group II: electrophysiological mapping and ablation with cryotherapy (CRYO) focal lesion formation.
The primary outcome will be the recurrence rate of accessory pathway conduction after one year of follow-up. Secondary endpoints will be immediate success and rate of permanent atrioventricular (AV) block.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Will be evaluated if percutaneous radiofrequency catheter ablation is superior to cryotherapy as treatment modality of para-hisian accessory pathways.
Will be evaluated if percutaneous cryotherapy catheter ablation is superior to radiofrequency as treatment modality of para-hisian accessory pathways.
Time frame: One year
Recurrence rate of accessory pathway conduction, as assessed by follow-up Clinical recording and event monitoring external device (Holter/Looper).
Time frame: Time span between vein puncture (start of procedure) and sheath removal (end of procedure), comparing with baseline rhythm
Mensuration of immediate success at the EP lab after ablation therapy is finished, defined by elimination of accessory pathway and/or noninducibility of arrhythmias at the end of procedure, as assessed by standard electrophysiological maneuvers.
If an evidence of accessory pathway conduction still remains at the end of procedure it will count as an unsuccessful case.
Does not take into account recurrences after the end of procedure, e.g. in the hospital ward before discharge.
Time frame: up to 24 hours
Safety outcome of any permanent atrioventricular (AV) block that occurred immediately after ablation start or during hospital admission.
University of Sao Paulo General Hospital
Other
Safety and Efficacy of Cryotherapy Versus Radiofrequency Ablation for Treatment of Para-hisian Accessory Pathways: a Randomized Comparative Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07725445
Arrhythmias, Cardiac, Cardiac Arrhythmias
Seoul, South Korea
View Trial DetailsNCT03505801
Arrhythmias, Cardiac, Atrial Fibrillation
Jonesboro, Arkansas, United States
View Trial DetailsNCT07402798
Arrhythmias, Cardiac, Atrial Fibrillation
Barcelona, Barcelona, Spain, Spain
View Trial DetailsNCT01509378
Arrhythmias, Cardiac, Cardiac Arrhythmias
Basel, Canton of Basel-City, Switzerland
View Trial Details